Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

CNS Neurosci Ther. 2022 Jun;28(6):971-973. doi: 10.1111/cns.13841. Epub 2022 Apr 12.

Authors

Robert Hoepner¹, Christian P Kamm^{1

2}, Christoph Friedli¹, Anke Salmen¹, Andrew Chan¹

Affiliations

¹ Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
² Neurocentre, Cantonal Hospital Lucerne, Lucerne, Switzerland.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Humans
Multiple Sclerosis* / complications
Multiple Sclerosis* / drug therapy
Neuromyelitis Optica* / complications
Neuromyelitis Optica* / drug therapy
T-Lymphocytes